CTIS2023-508018-41-00进行中（未招募）1 期
Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ETMF) - SRA-MMB-4365/219627
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 335
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •For subjects continuing MMB treatment: - Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301, For subjects continuing MMB treatment: - Able to comprehend and willing to sign the informed consent form
排除标准
- •Known hypersensitivity to MMB, its metabolites, or formulation excipient
研究者
相似试验
进行中（未招募）
1 期
Extended Access of Momelotinib for Subjects with MyelofibrosisPrimary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004350-42-ITSierra Oncology, Inc.400
进行中（未招募）
1 期
Extended Access of Momelotinib for Subjects with MyelofibrosisPrimary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004350-42-BGGlaxoSmithKline Research & Development Limited400
进行中（未招募）
1 期
Extended Access of Momelotinib for Subjects with MyelofibrosisPrimary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004350-42-ROGilead Sciences, Inc.200
进行中（未招募）
1 期
Extended Access of Momelotinib for Subjects with MyelofibrosisPrimary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004350-42-DKGlaxoSmithKline Research & Development Limited400
进行中（未招募）
1 期
Extended Access of Momelotinib for Subjects with MyelofibrosisPrimary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004350-42-DEGlaxoSmithKline Research @ Development Limited400